© Reuters.

FRANKFURT (Reuters) – German biotech firm CureVac has agreed to an alliance with drugmaker Bayer (OTC:) to get global support in seeking approval for its experimental COVID-19 vaccine and for distribution, daily Bild reported.

Under the deal, Germany’s Bayer will provide access to international pharmaceutical markets as well as its global supply chain and distribution network, the tabloid newspaper reported in an excerpt made available to Reuters ahead of publication. The report did not specify its sources.

The report did not disclose financial terms.

Bayer and CureVac were not immediately available for comment.

CureVac last month started a large Phase 2b/3 clinical trial of its COVID-19 vaccine candidate, banking on the same technology that has allowed rivals BioNTech and Moderna (NASDAQ:) to lead the development race.

Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures) and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn`t bear any responsibility for any trading losses you might incur as a result of using this data.

Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.

Source link

Leave a Reply

Your email address will not be published. Required fields are marked *